Image from breakthrought1d.org: What the 2026 ADA Conference Revealed About Islet Cell Therapy Progress

breakthrought1d.org (via breakthrought1d.org) / Source publication — credited and linked

Cure & Advancements/June 6, 2026/2 min read

What the 2026 ADA Conference Revealed About Islet Cell Therapy Progress

Researchers gathering in New Orleans highlighted both promise and challenges in developing cell-based treatments for Type 1 diabetes. A key focus: making clinical trials more accessible to patients who could benefit.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Over 100 studies on cell therapies, disease-modifying treatments, and diabetes technology were presented at the 2026 ADA conference, one of the world's largest diabetes research gatherings.
Current clinical trial eligibility requirements are too restrictive, limiting how many people with Type 1 diabetes can participate and slowing research progress.
Patient experiences and outcomes matter—regulators need documented evidence that people with Type 1 diabetes want and can benefit from islet cell replacement therapy.
Making islet cell therapies widely available will require establishing standard methods to measure what matters most to patients.

A Major Diabetes Research Conference Showcases Cell Therapy Progress

In June 2026, the American Diabetes Association (ADA) conference brought together more than 11,000 researchers, clinicians, healthcare professionals, and industry experts in New Orleans. The event highlighted cutting-edge work across multiple approaches to treating and potentially preventing Type 1 diabetes, including cell therapies, disease-modifying treatments, and new diabetes technologies.

Breakthrough T1D, a leading research funder, had researchers and staff on site sharing updates on studies they support. Over 100 presentations spanned different research directions, reflecting the breadth of work underway in the Type 1 diabetes field.

Islet Cell Therapy Shows Promise—But Trials Are Too Narrow

Manufactured islet cell therapies—which aim to replace the insulin-producing cells damaged by Type 1 diabetes—were a major focus of discussion. Sanjoy Dutta, Ph.D., Chief Scientific Officer at Breakthrough T1D, participated in a panel on advancing these therapies toward real-world clinical use.

A key finding emerged: the eligibility requirements for current clinical trials are too restrictive. These narrow criteria mean fewer people with Type 1 diabetes can enroll, and trials progress more slowly than they could. Researchers emphasized that broadening who can participate would help more patients benefit and accelerate the pace of research.

Patient Voice and Evidence Matter for Regulatory Approval

For islet cell therapies to become widely available, regulators need solid evidence that people with Type 1 diabetes actually want these treatments and that they work in real-world settings. This requires measuring what patients care about most—outcomes that go beyond traditional clinical metrics.

Conference discussions highlighted the need for established, systematic methods to document patient experiences and preferences. This patient-centered approach will be essential to convincing regulators that islet cell replacement therapy is a viable option for many people living with Type 1 diabetes.

Evidence label

Origin: breakthrought1d.org (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.